Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.51 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | YAP1 | P46937 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16986959 | 0.91 | TACR1 (0.57) | TACR1STSYAP1OPRD1OPRK1 | |
| SCHEMBL24859872 | 0.89 | TACR1 (0.52) | TACR1STSYAP1OPRD1OPRK1 | |
| SCHEMBL24859870 | 0.88 | TACR1 (0.55) | TACR1STSYAP1OPRD1OPRK1 | |
| SCHEMBL20493174 | 0.85 | TACR1 (0.52) | TACR1STSYAP1OPRD1OPRK1 | |
| SCHEMBL20493175 | 0.85 | TACR1 (0.52) | TACR1STSYAP1OPRD1OPRK1 | |
| SCHEMBL14881069 | 0.84 | TACR1 (0.44) | TACR1ALDH1A1TSHR | |
| SCHEMBL18063149 | 0.83 | TACR1 (0.43) | TACR1ALDH1A1TSHR | |
| SCHEMBL22981606 | 0.82 | KMT2A (0.54) | TACR1KDM4EMEN1KMT2A | |
| SCHEMBL1446835 | 0.81 | TACR1 (0.60) | TACR1STSOPRD1OPRK1GPR119 | |
| SCHEMBL1447994 | 0.81 | TACR1 (0.55) | TACR1OPRD1OPRK1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159505-A1 | AMINES FOR USE AS SIGMA RECEPTOR MODULATORS | Ecstasy LLC | 2023-05-25 | — | — | US | disclosed |
| US-11548879-B1 | Polycyclics as sigma receptor modulators | Ecstasy LLC (US) | 2023-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159505-A1 | AMINES FOR USE AS SIGMA RECEPTOR MODULATORS | SIGMAR1, OPRM1, OPRK1 | TACR1 11/4885STS 1477/4885YAP1 2064/4885 |
| US-11548879-B1 | Polycyclics as sigma receptor modulators | SIGMAR1, OPRM1, OPRK1 | TACR1 10/4885STS 1316/4885YAP1 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.